Quick Answer
Sigyn Therapeutics, Inc. reported Stockholders Equity of -$4.46 million for the year ending 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -30.6% in Stockholders Equity from 2023 to 2024.
- This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: -$82.0 thousand | Q1 2016: -$414.8 thousand | Q2 2016: -$975.2 thousand | Q3 2016: -$1.24 million | Q1 2018: -$2.40 million | Q2 2018: $2.46 million | Q3 2018: -$2.68 million | Q4 2018: -$3.72 million | Q1 2019: -$3.66 million | Q2 2019: -$3.78 million | Q3 2019: -$3.92 million | Q1 2020: $50.1 thousand | Q2 2020: -$188.7 thousand | Q3 2020: -$455.0 thousand | Q1 2021: -$80.3 thousand | Q2 2021: $977.1 thousand | Q3 2021: $358.2 thousand | Q1 2022: -$731.6 thousand | Q2 2022: -$1.18 million | Q3 2022: -$1.74 million | Q1 2023: -$2.35 million | Q2 2023: -$3.04 million | Q3 2023: -$3.58 million | Q4 2023: -$3.41 million | Q1 2024: -$4.02 million | Q2 2024: -$3.67 million | Q3 2024: -$3.92 million | Q4 2024: -$4.46 million | Q1 2025: -$4.95 million | Q2 2025: -$5.44 million | Q3 2025: -$5.92 million.
- Over the full 12 years of available data (2013 to 2024), Sigyn Therapeutics, Inc.'s Stockholders Equity has declined by 18,274.4%.
- Historical annual values: Fiscal year 2024: -$4.46 million | Fiscal year 2023: -$3.41 million | Fiscal year 2022: -$1.90 million | Fiscal year 2021: -$264.6 thousand | Fiscal year 2020: $99.2 thousand | Fiscal year 2019: -$910.00 | Fiscal year 2018: -$3.72 million | Fiscal year 2017: -$2.09 million | Fiscal year 2016: -$691.8 thousand | Fiscal year 2015: -$82.0 thousand | Fiscal year 2014: $99.4 thousand | Fiscal year 2013: $24.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: